Zobrazit v EDS

The gut microbiota during tamoxifen therapy in patients with breast cancer

Uloženo v:
Podrobná bibliografie
Název: The gut microbiota during tamoxifen therapy in patients with breast cancer
Autoři: Lars E. Hillege, David J. M. Barnett, Janine Ziemons, Romy Aarnoutse, Judith de Vos-Geelen, Robin van Geel, Maaike de Boer, Yvonne E. A. van Riet, Jeroen Vincent, John Penders, Marjolein L. Smidt
Zdroj: Sci Rep
Scientific Reports, Vol 15, Iss 1, Pp 1-12 (2025)
Informace o vydavateli: Springer Science and Business Media LLC, 2025.
Rok vydání: 2025
Témata: Feces/microbiology, Tamoxifen/therapeutic use pharmacology analogs & derivatives, Antineoplastic Agents, Hormonal, Science, Antineoplastic Agents, Breast Neoplasms, Article, Feces, RNA, Ribosomal, 16S, Antineoplastic agents, Humans, Gastrointestinal Microbiome/drug effects, Prospective Studies, Hormonal/therapeutic use, Aged, Ribosomal, Middle Aged, Gastrointestinal Microbiome, Postmenopause, Tamoxifen, Breast Neoplasms/drug therapy microbiology metabolism, RNA, Medicine, Postmenopausal, Female, Breast neoplasms, 16S/genetics
Popis: Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the effects of tamoxifen on gut microbiota composition in postmenopausal ER+ and human epidermal growth factor receptor 2 negative (HER2-) breast cancer patients and explores correlations between gut microbiota and endoxifen plasma levels. This prospective observational study included postmenopausal ER+/HER2- breast cancer patients. Fecal and blood samples were collected before and during 6-12 weeks of tamoxifen therapy. Gut microbiota composition was analyzed using 16S rRNA amplicon sequencing of the hypervariable V4 gene region, and plasma endoxifen levels were measured using liquid chromatography-mass spectrometry. Changes in microbial diversity and composition were assessed, with correlations to endoxifen levels. A total of 62 patients were included. Tamoxifen significantly increased microbial richness (p = 0.019), although overall community structure remained consistent between pre- and during-treatment samples. Notable changes were observed in specific microbial taxa, with significant increases in genera such as Blautia (padjusted = 0.003) and Streptococcus (padjusted = 0.010), and decreases in Prevotella_9 (padjusted = 0.006). No significant correlations between gut microbiota and endoxifen levels were identified after multiple comparisons. Tamoxifen therapy increases gut microbial diversity in postmenopausal ER+/HER2- breast cancer patients, though overall microbial community structure remains stable. The absence of significant correlations with endoxifen levels suggests that while tamoxifen affects the gut microbiota, its role in endoxifen metabolism requires further study. More comprehensive research is needed to understand the relationship between tamoxifen, gut microbiota, and therapeutic outcomes.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 2045-2322
DOI: 10.1038/s41598-025-91734-1
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/40050324
https://doaj.org/article/d0c979e93b0a4833a1a5df373006e020
https://cris.maastrichtuniversity.nl/en/publications/3dfb9994-4daf-4d55-9363-a86ddd3f0395
https://doi.org/10.1038/s41598-025-91734-1
Rights: CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....fffa00616892813bf66c5fbfb5dd23d9
Databáze: OpenAIRE
Popis
Abstrakt:Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the effects of tamoxifen on gut microbiota composition in postmenopausal ER+ and human epidermal growth factor receptor 2 negative (HER2-) breast cancer patients and explores correlations between gut microbiota and endoxifen plasma levels. This prospective observational study included postmenopausal ER+/HER2- breast cancer patients. Fecal and blood samples were collected before and during 6-12 weeks of tamoxifen therapy. Gut microbiota composition was analyzed using 16S rRNA amplicon sequencing of the hypervariable V4 gene region, and plasma endoxifen levels were measured using liquid chromatography-mass spectrometry. Changes in microbial diversity and composition were assessed, with correlations to endoxifen levels. A total of 62 patients were included. Tamoxifen significantly increased microbial richness (p = 0.019), although overall community structure remained consistent between pre- and during-treatment samples. Notable changes were observed in specific microbial taxa, with significant increases in genera such as Blautia (padjusted = 0.003) and Streptococcus (padjusted = 0.010), and decreases in Prevotella_9 (padjusted = 0.006). No significant correlations between gut microbiota and endoxifen levels were identified after multiple comparisons. Tamoxifen therapy increases gut microbial diversity in postmenopausal ER+/HER2- breast cancer patients, though overall microbial community structure remains stable. The absence of significant correlations with endoxifen levels suggests that while tamoxifen affects the gut microbiota, its role in endoxifen metabolism requires further study. More comprehensive research is needed to understand the relationship between tamoxifen, gut microbiota, and therapeutic outcomes.
ISSN:20452322
DOI:10.1038/s41598-025-91734-1